Asia Pacific Anti-Obesity Drugs Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031

The Asia Pacific Anti-Obesity Drugs Market size is expected to reach US$ 15,476.6 Million by 2031 from US$ 1,317.2 Million in 2024. The market is estimated to record a CAGR of 45.7% from 2025 to 2031.

Executive Summary and Asia Pacific Anti-Obesity Drugs Market Analysis:

The Asia Pacific anti-obesity drugs market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the market is driven by several key factors. Rising urbanization and sedentary lifestyles have led to a significant increase in obesity rates across countries like China, India, and Australia. Rapid economic development has also resulted in greater consumption of high-calorie, processed foods. Additionally, growing awareness of the health risks associated with obesity-such as diabetes, cardiovascular disease, and certain cancers-has boosted demand for effective weight management solutions. Government initiatives promoting healthier lifestyles and preventive healthcare are also contributing to market expansion. Furthermore, advancements in pharmaceutical research and increased accessibility to healthcare services are enabling wider availability of anti-obesity medications. Rising disposable incomes and expanding middle-class populations in emerging markets further support this trend. Finally, social and cultural shifts toward body image consciousness are influencing individuals to seek pharmacological options for weight loss, fueling sustained growth in the anti-obesity drug market across the region.

Asia Pacific Anti-Obesity Drugs Market: Strategic Insights

Asia Pacific Anti-Obesity Drugs Market Segmentation Analysis:

• By Type, the Asia Pacific Anti-Obesity Drugs Market is segmented into Prescription Drugs and OTC Drugs. Prescription Drugs held the largest share of the market in 2024.
• By Mechanism of Action, the Asia Pacific Anti-Obesity Drugs Market is segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others. Centrally Acting Drugs held the largest share of the market in 2024.
• By Drug Class, the Asia Pacific Anti-Obesity Drugs Market is segmented into GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others. GLP-1 Agonist held the largest share of the market in 2024.
• By GLP-1 agonist, the Asia Pacific Anti-Obesity Drugs Market is segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound). Semaglutide held the largest share of the market in 2024.
• By Application, the Asia Pacific Anti-Obesity Drugs Market is segmented into Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination. Appetite Suppression held the largest share of the market in 2024.
• By Route of Administration, the Asia Pacific Anti-Obesity Drugs Market is segmented into Oral and Parenteral. Oral held the largest share of the market in 2024.
• By Distribution Channel, the Asia Pacific Anti-Obesity Drugs Market is segmented into Hospital Pharmacies, Online Channel, and Retail Pharmacies. Hospital Pharmacies held the largest share of the market in 2024.

Asia Pacific Anti-Obesity Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Anti-Obesity Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Anti-Obesity Drugs Market Outlook

Expansion in emerging economies presents a significant opportunity for the anti-obesity drugs market due to rising obesity rates driven by urbanization and lifestyle changes. Increasing healthcare infrastructure and growing awareness about obesity-related health risks are encouraging demand for effective treatments. Additionally, improving access to healthcare and pharmaceuticals in these regions supports market growth. Pharmaceutical companies are investing in these markets to tap into the unmet need for weight management solutions. As a result, emerging economies are becoming key growth drivers for the global anti-obesity drugs market. According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.

According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6-9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. For instance, Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. The rising obesity prevalence in emerging economies, combined with expanding healthcare infrastructure and growing awareness, is driving increased demand for anti-obesity drugs. Pharmaceutical investments and government initiatives are fostering an environment conducive to market growth. Although initial access may be limited by cost, future insurance coverage and generic options are expected to enhance accessibility. These factors collectively position emerging markets as key growth areas for the global anti-obesity drugs market.

Asia Pacific Anti-Obesity Drugs Market Country Insights

By country, the Asia Pacific Anti-Obesity Drugs Market is segmented into China, Japan, India, Australia, South Korea, Rest of APAC. China held the largest share in 2024.

The Global Health Journal stated in September 2022 that obesity has become a severe public health issue worldwide. China has the world's largest number of overweight people. Over 50% of adults and ~20% of children and adolescents in China are overweight. An article titled "China Facing Obesity Crisis as Forecasts Predict 65% Will Be Overweight by 2030," published in April 2025, reports that in 2021, over 400 million adults in China were classified as overweight or obese. This figure surpassed the 172 million adults in the US. This number is expected to increase to 630 million by 2050.

This surge is attributed to rapid urbanization, sedentary lifestyles, and dietary shifts toward high-fat, high-sugar foods. Consequently, obesity has become a pressing public health concern, prompting both governmental and corporate entities to seek effective solutions. This escalating health crisis is encouraging both domestic and international pharmaceutical companies to invest in anti-obesity treatments. Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, have gained popularity in China, with Ozempic's sales nearly doubling in 2023 to approximately US$ 700 million. These GLP-1 receptor agonists have been endorsed by influencers and social media platforms, further boosting their appeal. Similarly, in August 2024, Eli Lilly's tirzepatide, another GLP-1 receptor agonist, received approval in China for obesity treatment, intensifying competition in the market.

Asia Pacific Anti-Obesity Drugs Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC., AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Anti-Obesity Drugs Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise